US Patent Issued to PHARMA MAR on Oct. 27 for "Combination of lurbinectedin and immune checkpoint inhibitors" (French Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,773,405, issued on Oct. 27, was assigned to PHARMA MAR S.A. (Madrid).

"Combination of lurbinectedin and immune checkpoint inhibitors" was invented by Guido Kroemer (Villejuif, France) and Oliver Kepp (Villejuif, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described are combination therapies for the treatment of solid tumours, said therapies comprising lurbinectedin and an immune checkpoint inhibitor, for example, anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies."

The patent was filed on April 25, 2025, under Application No. 19/190,098.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/...